Updated: December 24, 2021 11:27:55 am
A new study by researchers at the University of Oxford has found that a booster dose of the AstraZeneca vaccine was able to significantly increase the levels of neutralising antibodies against the Omicron variant of the coronavirus, offering hope that the vaccine could offer some protection against the fast-spreading variant.
The AstraZeneca vaccine, being marketed under the brand names Covishield, manufactured in India, and Vaxzevria, produced in South Korea, was developed at the laboratories of the University of Oxford. The current study was conducted by a different team of researchers at the same university.
Newsletter | Click to get the day’s best explainers in your inbox
The study found that sera obtained from individuals one month after receiving the third dose was able to neutralise the Omicron variant to levels that were comparable to those observed against the Delta variant one month after the second dose.
Also, the levels of neutralising antibodies after the third dose were found to be higher than those observed in individuals who had been previously infected with other variants, including Delta, and recovered on their own, the company said in a statement.
Studies on other vaccines like Moderna or Pfizer have also suggested that their third doses offered some protection against the Omicron variant, although with reduced effectiveness compared to their action against the Delta variant.
Covishield accounts for more than 85 per cent of all vaccines given in India. For that reason, it is not considered an ideal vaccine for the booster doses. Health experts have maintained, and several studies have shown, that booster doses work best if a vaccine different from the primary doses is used.
A couple of days ago, AstraZeneca had also unveiled its plans for developing an Omicron-specific vaccine.
Amid a rapid surge in infections with the Omicron variant, several countries in Europe have begun vaccinating children below 12 years of age. In most of the world, only people above the age of 18 have been vaccinated because of very low prevalence of coronavirus cases in younger age groups. A few countries later opened up vaccinations for the 12-18 age group as well.
But the unvaccinated people, even in the younger age groups, are being considered vulnerable to the Omicron variant. A recent study in France found infection among children in the 6-10 age group to be twice that among the large population, The New York Times reported. A similar pattern has been observed in Italy where schoolchildren and young adults account for the majority of recent cases, the newspaper said.
France has now said it would provide vaccines to everyone above the age of five. Germany, Greece, Spain and the United States, too, have opened up vaccinations for children.
Four of the 23 Omicron cases discovered in Maharashtra and three out of seven in Gujarat on Thursday were among people below the age of 18 years.
UK surge continues
The United Kingdom had the second consecutive day of record-breaking number of new coronavirus cases on Thursday. It reported more than 1.19 lakh cases in a 24-hour period, after detecting over 1.06 lakh the previous day.
Spain too registered its highest single-day count of new cases, with more than 50,000 infections being reported on Thursday. In France, the daily count of cases now exceeds 70,000 and the country’s health minister had warned that it would soon cross the 1 lakh mark
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.